Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|May 6, 2026
[Pediatric drug development: current landscape, challenges, and future directions]Chie Emoto, Tsuyoshi Fukuda
Therapeutic Drug Monitoring|June 17, 2016
Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant PatientsChie Emoto, Alexander A Vinks, Tsuyoshi Fukuda
British Journal of Clinical Pharmacology|August 11, 2015
The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic modelChie Emoto, Tsuyoshi Fukuda, Raja Venkatasubramanian, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 27, 2016
Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to ChildrenDavid Hahn, Chie Emoto, Alexander A Vinks, et al.
European Journal of Clinical Pharmacology|February 2, 2021
Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its dispositionChie Emoto, Trevor N Johnson, Takaaki Yamada, et al.
Biopharmaceutics & Drug Disposition|November 7, 2019
Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modelingMiki Ota, Makiko Shimizu, Yusuke Kamiya, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 16, 2018
Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK ObservationsChie Emoto, Trevor N Johnson, Brooks T McPhail, et al.
Therapeutic Drug Monitoring|October 11, 2021
Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical InformationTakaaki Yamada, Chie Emoto, Tsuyoshi Fukuda, et al.
Clinical Pharmacology and Therapeutics|October 10, 2018
Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical StudyDavid Hahn, Chie Emoto, Joshua C Euteneuer, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 20, 2018
PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small InfantsChie Emoto, Trevor N Johnson, Sibylle Neuhoff, et al.
Pageof 14